Mannkind Corporation

MNKD Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of MNKD by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
MNKD Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
MNKD Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
MNKD Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in MNKD holdings by institutional investors

Insider Trading

Quarterly net insider trading by MNKD's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $30,000 Oct 20, 2023 Issue: Health Issues
  • $30,000 Jan 19, 2023 Issue: Health Issues
  • $30,000 Oct 18, 2022 Issue: Health Issues
  • $20,000 Apr 20, 2022 Issue: Health Issues
  • $30,000 Jan 20, 2022 Issue: Health Issues
  • $30,000 Oct 20, 2021 Issue: Medicare/Medicaid
  • $30,000 Jul 21, 2021 Issue: Medicare/Medicaid
  • $30,000 Jun 22, 2021 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
Corporate Lobbying

MNKD Estimated quarterly lobbying spending

Revenue Breakdown

MNKD Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
MNKD Income Statement
MNKD Balance Sheet
MNKD Cash Flow
U.S. Patents

New MNKD patent grants

  • Patent Title: Inhaler Jun. 18, 2019
  • Patent Title: Inhaler Feb. 26, 2019
  • Patent Title: Inhaler Nov. 20, 2018
  • Patent Title: Inhaler Jul. 31, 2018
  • Patent Title: Inhaler Jul. 24, 2018
  • Patent Title: Inhaler Jul. 24, 2018
  • Patent Title: Apparatus, system and method for measuring resistance of an inhaler May. 29, 2018
  • Patent Title: Formation of n-protected bis-3,6-(4-aminobutyl)-2, 5-diketopiperazine through a cyclic alpha-n-protected amino ester Apr. 17, 2018
  • Patent Title: Use of ultrarapid acting insulin Apr. 17, 2018
  • Patent Title: Heat-stable dry powder pharmaceutical compositions and methods Mar. 27, 2018
  • Patent Title: Mouthpiece cover Nov. 07, 2017
  • Patent Title: Dry powder drug delivery system and methods Oct. 31, 2017
  • Patent Title: Potentiation of glucose elimination Oct. 31, 2017
  • Patent Title: Catalysis of diketopiperazine synthesis Oct. 24, 2017
  • Patent Title: Powder dispensing and sensing apparatus and methods Sep. 26, 2017
  • Patent Title: Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents Aug. 01, 2017
  • Patent Title: Apparatus and method for simulating inhalation efforts Jul. 18, 2017
  • Patent Title: Inhalation apparatus Jul. 11, 2017
  • Patent Title: Ire-1α inhibitors Jul. 04, 2017
  • Patent Title: Diketopiperazine salts for drug delivery and related methods Jun. 13, 2017
  • Patent Title: Dry powder drug delivery system and methods May. 30, 2017
  • Patent Title: Substituted diketopiperazine analogs for use as drug delivery agents May. 23, 2017
  • Patent Title: Diketopiperazine microparticles with defined specific surface areas Apr. 25, 2017
  • Patent Title: Determining percent solids in suspension using raman spectroscopy Apr. 18, 2017
  • Patent Title: Methods and compositions for treating pain Apr. 04, 2017
  • Patent Title: Use of ultrarapid acting insulin Mar. 21, 2017
  • Patent Title: Apparatus and method for cryogranulating a pharmaceutical composition Feb. 14, 2017
  • Patent Title: Ire-1α inhibitors Jan. 17, 2017
  • Patent Title: Dry powder inhaler and system for drug delivery Dec. 06, 2016
  • Patent Title: Mouthpiece cover Nov. 08, 2016
  • Patent Title: Dry powder inhaler and system for drug delivery Sep. 20, 2016
  • Patent Title: Increasing drug affinity for crystalline microparticle surfaces Sep. 20, 2016
  • Patent Title: Formation of n-protected bis-3,6-(4-aminoalkyl)-2,5,diketopiperazine Aug. 16, 2016
  • Patent Title: Inhaler device Jan. 22, 2013
  • Patent Title: Blister packaging Dec. 04, 2012
  • Patent Title: Cartridge for a dry powder inhaler Jul. 31, 2012
  • Patent Title: Blister packaging Aug. 16, 2011
  • Patent Title: Dry powder inhaler Apr. 26, 2011
  • Patent Title: Dry powder inhaler Apr. 26, 2011
  • Patent Title: Dry powder inhaler Apr. 26, 2011
  • Patent Title: Dry powder inhaler Mar. 29, 2011
  • Patent Title: Dry powder inhaler Mar. 29, 2011
  • Patent Title: Dry powder inhaler Mar. 29, 2011
  • Patent Title: Dry powder inhaler Dec. 28, 2010
  • Patent Title: Dry powder inhaler Dec. 28, 2010
  • Patent Title: Dry powder inhaler Dec. 28, 2010
  • Patent Title: Dry powder inhaler Dec. 21, 2010
  • Patent Title: Dry powder inhaler Dec. 21, 2010
  • Patent Title: Dry powder inhaler Apr. 27, 2010
  • Patent Title: Cartridge for a dry powder inhaler Apr. 13, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to MNKD from public contracts

MNKD News

Recent insights relating to MNKD

CNBC Recommendations

Recent picks made for MNKD stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MNKD

MNKD Analyst Ratings

MNKD Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
MNKD Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $MNKD stock a Buy, Sell, or Hold?

  • What is the price target for $MNKD stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

MNKD Top Shareholders
Shareholder
Shares Held
MNKD Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $MNKD stock?

  • Who owns the most shares of $MNKD stock?

  • What funds own $MNKD stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

MNKD Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view MNKD Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About MNKD

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

  • Address Danbury, CT
  • Market Cap 1.5 billion
  • Employees 407
  • Industrial Classification Pharmaceutical Preparations
Back To Top